Book ChapterDOI
Application of Microbial Toxins for Cancer Therapy
Rama Shanker Verma,Sirisha Potala,Mrudula Mathew,Swati Choudhary +3 more
- pp 647-662
TLDR
Continuous efforts are being made to improve the specificity and efficacy of immunotoxins, to reduce size effects of the drugs, reduce immunogenicity and to improve better pharmacokinetics for drugs delivery.Abstract:
The principle of selective targeting of immunotoxins lies on the basis that cancer cells usually have few or specific growth factors/receptors/antigens highly over expressed on their surface. Ligands corresponding to these molecules are conjugated to modified toxins (modified to loss its native function) isolated form variety of bacterial populations. Normal cells either do not express these molecules or express at relatively low number leading to no or minimal adverse effects. The basic mechanism of action of these immunotoxins depends on the toxins employed. In this regard continuous efforts are being made to (i) Identity molecules exclusively expressed in cancer cells, (ii) to improve the specificity and efficacy (iii) reduce size effects of the drugs, (iv) Reduce immunogenicity and (v) to improve better pharmacokinetics for drugs delivery.read more
Citations
More filters
Journal ArticleDOI
In Silico Analyses of Staphylococcal Enterotoxin B as a DNA Vaccine for Cancer Therapy
TL;DR: Assessment of the immunoreactivity of a SEB-coding DNA construct that serves as a DNA vaccine for breast cancer therapy revealed that apparently the construct could be efficiently expressed in mouse model, and could act as an amenable adjuvant in cancer immunotherapy.
References
More filters
Journal ArticleDOI
Characterization and receptor specific toxicity of two diphtheria toxin-related interleukin-3 fusion proteins DAB389–mIL-3 and DAB389–(Gly4Ser)2-mIL-3
Dominique Liger,Johanna C. vanderSpek,Carole Gaillard,Christophe Cansier,John R. Murphy,Philippe Leboulch,Philippe Leboulch,Daniel Gillet +7 more
TL;DR: Two fusion proteins are constructed in which the receptor‐binding domain of diphtheria toxin is replaced by mouse interleukin‐3 (IL‐3), and Cytotoxic activity of the fusion toxins was observed on three out of six cell lines assayed.
Journal ArticleDOI
New molecules and strategies in the field of anticancer agents.
TL;DR: This review will be focused mainly on three different classes of compounds designed to hit or inhibit crucial molecular targets, including novel DNA minor groove binders, and products of marine origin that exhibit novel mode of action.
Journal ArticleDOI
DAB389 Interleukin-2 Receptor Binding Domain Mutations CYTOTOXIC PROBES FOR STUDIES OF LIGAND-RECEPTOR INTERACTIONS
Johanna C. vanderSpek,John A. Sutherland,Monthakan Ratnarathorn,Kimberly Howland,Thomas L. Ciardelli,Thomas L. Ciardelli,John R. Murphy +6 more
TL;DR: Site-directed mutagenesis was used to generate point mutations in the diphtheria toxin-related fusion protein, DAB389 interleukin-2 (IL-2), and Thr-439, in the IL-2 receptor binding domain of the fusion toxin, was changed to a Pro residue.
Journal ArticleDOI
A new mouse model for renal lesions produced by intravenous injection of diphtheria toxin A-chain expression plasmid
Shingo Nakamura,Shingo Nakamura,Masuo Terashima,Natsuko Kikuchi,Minoru Kimura,Tadaaki Maehara,Akira Saito,Masahiro Sato +7 more
TL;DR: A novel method to produce mouse models of renal failure by intravenous injection of a plasmid carrying a toxic gene such as diphtheria toxin A-chain (DT-A) gene, which caused temporary abnormalities mainly in glomeruli of mouse kidney.
Journal ArticleDOI
Recombinant hybrid toxin with dual enzymatic activities. Potential use in preparing highly effective immunotoxins.
Bi Yu Li,S. Ramakrishnan +1 more
TL;DR: The results indicate that the hybrid toxin with dual activities could be useful in preparing potent immunotoxins with better anti-tumor cell activity.